Bank of America raised its price target on Hims & Hers Health, but still thinks you should sell the stock. February saw a spike in weight loss sales at the drug compounder, but future sales of ...

Hims & Hers offers both branded and cheaper versions of Novo's weight-loss drug Wegovy. (Image Credits: Pixabay) Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli ...

Hims & Hers Health HIMS-7.15%decrease; red down pointing triangle said it is expanding its weight-loss offerings with the addition of Eli Lilly LLY-6.45%decrease; red down pointing triangle & Co ...

Hims & Hers Health (NYSE: HIMS) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target on the pharmaceuticals stock in the worst way possible. BofA added only ...

Hims & Hers will begin selling branded GLP-1 weight loss drugs from Eli Lilly. The FDA recently ended the company's temporary permission to compound similar GLP-1 drugs, which was set to take a ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...

Russia continues its Black Sea clean-up operation in the Kerch Strait, after last December’s oil spill from two storm-stricken Russian tankers, according to Russian authorities. Russia is ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed ...